Mind Medicine Inc’s filing revealed that its Chief Executive Officer Barrow Robert unloaded Company’s shares for reported $0.14 million on Dec 26 ’24. In the deal valued at $7.43 per share,19,106 shares were sold. As a result of this transaction, Barrow Robert now holds 526,666 shares worth roughly $3.2 million.
Then, Liao Carrie sold 2,273 shares, generating $16,888 in total proceeds. Upon selling the shares at $7.43, the Chief Accounting Officer now owns 97,270 shares.
Before that, Karlin Dan sold 6,643 shares. Mind Medicine Inc shares valued at $49,357 were divested by the Chief Medical Officer at a price of $7.43 per share. As a result of the transaction, Karlin Dan now holds 338,013 shares, worth roughly $2.05 million.
Evercore ISI initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on January 28, 2025; the price target was $23. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. ROTH MKM started covering the stock on July 24, 2024. It rated MNMD as “a Buy”.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock fall -9.67% to $6.07. Over the last five days, the stock has lost -15.46%. Mind Medicine Inc shares have fallen nearly -12.79% since the year began. Nevertheless, the stocks have risen 13.46% over the past one year. While a 52-week high of $12.22 was reached on 02/14/25, a 52-week low of $5.03 was recorded on 03/03/25. SMA at 50 days reached $7.43, while 200 days put it at $7.20.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 5.77, which if violated will result in even more drops to 5.47. On the upside, there is a resistance level at 6.63. A further resistance level may holdings at 7.19. The Relative Strength Index (RSI) on the 14-day chart is 35.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.23, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.09%. Stochastics %K at 3.22% indicates the stock is a buying.
The most recent change occurred on May 29, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $27 price target.
